Semaglutide drugs like Ozempic, used for diabetes and off-label weight loss, are linked to reports of 'Ozempic personality'—emotional blunting and reduced pleasure in activities—based on patient testimonials and clinician observations. While sales reached over $13 billion for Novo Nordisk in 2023, the phenomenon highlights trade-offs between weight loss benefits and potential mood impacts. Debates center on evidence strength, policy responses, and individual choice.